Table 2.
Patient characteristics stratified on Flu exposure groups
| Variables | Within optimal exposure range (N = 101) | Above optimal exposure range (N = 79) | Below optimal exposure range (N = 12) |
|---|---|---|---|
| Age at transplantation, y*** | 23.5 (7.1-47, 0.23-70) | 56.7 (39-63, 0.29-74) | 13.7 (5.1-16, 1.9-32) |
| Sex | |||
| Male | 58 (57) | 48 (61) | 9 (75) |
| Female | 43 (43) | 31 (39) | 3 (25) |
| Indication*** | |||
| Benign | 44 (44) | 13 (16) | 11 (92) |
| Leukemia/lymphoma | 41 (41) | 30 (38) | |
| MDS | 11 (11) | 18 (23) | 1 (8.3) |
| Plasma cell disorder | 5 (5) | 18 (23) | |
| Cell source** | |||
| PB: Full graft | 10 (9.9) | 14 (18) | |
| Cord blood | 39 (39) | 15 (19) | 11 (92) |
| Bone marrow | 12 (12) | 4 (5.1) | |
| PB: α-β depleted | 40 (40) | 46 (58) | 1 (8.3) |
| Human leukocyte antigen disparity*,*** | |||
| Matched | 79 (78) | 66 (84) | 5 (42) |
| Mismatched | 22 (22) | 13 (16) | 7 (58) |
| Conditioning | |||
| Samples per patient | 10 (8-12, 3-19) | 9 (8-12, 3-15) | 10.5 (8-12, 6-16) |
| Flu AUCt0−∞, mg*h/L*** | 21.3 (19-23, 16-25) | 30.8 (27-36, 26-66) | 13.8 (13-15, 10-15) |
| Busulfan AUCt0−∞, mg*h/L | 95.3 (89-100, 59†-120) | 97.8 (91-100, 65-120) | 95.9 (90-100, 82-120) |
| Serotherapy | |||
| Patients without ATG | 13 (13) | 7 (8.9) | |
| Patients with ATG | 88 (87) | 72 (91) | 12 (100) |
| AUCtx−∞ of patients with ATG | 12 (1.6-35, 0-130) | 18 (4.4-43, 0-270) | 3.82 (2.8-9.1, 1.5-86) |
| Creatinine clearance, mL/min/1.73 m2*** | 121 (110-140, 40-140) | 100 (79-110, 25-140) | 140 (140-140, 110-140) |
| Median follow-up (95% CI), d | 688 (591-913) | 369 (341-493) | 884 (779-NA) |
Categorical variables are displayed as n (%). Continuous variables are displayed as median (interquartile range, range).
NA, not available.
*
In peripheral blood HCT, 90 were 10/10, 09/10, 16 were 8/8, and 3 were 6/6. In cord blood HCT, 4 were 10/10, 4 were 9/10, 3 were 8/10, 21 were 6/6, 24 were 5/6, and 9 were 4/6. In bone marrow HCT, all were matched 10/10.
†
Minima exclude Fanconi anemia patients (n = 3): for these patients, indication-specific myeloablation was achieved with AUCt0 −∞ of 31, 31, and 25 mg*h/L.
**
Values between groups are significantly different at level P < .01.
***
Values between groups are significantly different at level P < .001.